Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Measures Suggested for Drugs for Which Dissolution Tests Are Difficult: Quality Reevaluation
August 29, 2005
- Uncollected Medical Fees - Why Don't Patients Pay?
August 29, 2005
- REGULATORY NEWS IN BRIEF
August 29, 2005
- FDGscan May Dramatically Change Cancer Diagnosis in Japan
August 29, 2005
- Ono Announces Results of PII Study of Cereact for ALS
August 29, 2005
- FDGscan Also Provides Benefits to Existing PET Facilities
August 29, 2005
- R&D NEWS IN BRIEF
August 29, 2005
- AnGes MG, Avontec GmbH Sign Cross-licensing Agreement
August 29, 2005
- IMS Japan, ACNielsen Japan Launch OTC Market Analysis Tool
August 29, 2005
- Nippon Chemiphar Licenses NC-2300 to Velcura Therapeutics
August 29, 2005
- SELF-MEDICATION NEWS IN BRIEF
August 29, 2005
- Sales of Ethical Drugs Up 6% in April-June Period: IMS Japan
August 29, 2005
- JCQHC Analyzes 18 Surgical, 47 Drug-related Accidents
August 29, 2005
- Kainos to Strengthen Blood Transfusion Screening Business with Immucor
August 29, 2005
- Gov't-Managed Health Insurance Shows Surplus for 2nd Consecutive Year
August 29, 2005
- Toyobo Completes New Contract Production Facility in Otsu
August 29, 2005
- Spread of PET by FDG Delivery Service to Change Cancer Treatment Strategy
August 29, 2005
- BUSINESS NEWS IN BRIEF
August 29, 2005
- NEW PRODUCTS
August 29, 2005
- 1st Half Business Results
August 29, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…